The human genome sequencing project provides the foundation for using individual genetics to optimize the selection and dosing of medications. The field of pharmacogenomics is still young, but has undergone a revolution in the last decade, as genomic technologies have uncovered associations between drug response phenotypes and genetic variations. The challenge now is to define the mechanisms underlying these associations, to advance our detailed understanding of the genetics of drug response. The PharmGKB (www.pharmgkb.org/) is devoted to collecting, encoding and disseminating knowledge about pharmacogenomics. PharmGKB is the pre-eminent resource for information about genes involved in the pharmacokinetics (PK) and pharmacodynamics of drug response, the pathways in which they act, and their important polymorphisms. PharmGKB staff curate this information, and have also helped lead successful international data sharing initiatives. In this proposal, we outline a plan to (1) curate information about genetic variations, pathways and networks relevant to drug response (2) create informatics tools for understanding the mechanism of drug response, (3) create and support new data sharing consortia, (4) engage in strategic collaborations to maximize PharmGKB's impact, and (5) disseminate the PharmGKB resources to the scientific community. We provide testimonials from users and letters of support from the research community to demonstrate our ongoing impact on the field.
Pharmacogenomics is the study of how variations in human genes affect our response to drugs. It is the science behind personalized medicine-using individual genetics to increase the efficacy of drugs, and reduce their unwanted side effects. This proposal outlines a plan to extend the PharmGKB, a web-based resource that provides high-quality information and tools to researchers in pharmacogenomics.
|Schully, Sheri D; Lam, Tram Kim; Dotson, W David et al. (2015) Evidence synthesis and guideline development in genomic medicine: current status and future prospects. Genet Med 17:63-7|
|Province, M A; Altman, R B; Klein, T E (2014) Interpreting the CYP2D6 results from the International Tamoxifen Pharmacogenetics Consortium. Clin Pharmacol Ther 96:144-6|
|Daneshjou, Roxana; Zappala, Zachary; Kukurba, Kim et al. (2014) PATH-SCAN: a reporting tool for identifying clinically actionable variants. Pac Symp Biocomput :229-40|
|Lowenberg, Daniella; Thorn, Caroline F; Desta, Zeruesenay et al. (2014) PharmGKB summary: ifosfamide pathways, pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics 24:133-8|
|Relling, M V; McDonagh, E M; Chang, T et al. (2014) Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype. Clin Pharmacol Ther 96:169-74|
|McDonagh, Ellen M; Thorn, Caroline F; Callaghan, John T et al. (2014) PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics. Pharmacogenet Genomics 24:464-76|
|Alvarellos, Maria L; Lamba, Jatinder; Sangkuhl, Katrin et al. (2014) PharmGKB summary: gemcitabine pathway. Pharmacogenet Genomics 24:564-74|
|Province, M A; Goetz, M P; Brauch, H et al. (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-27|
|Gong, Li; Stamer, Ulrike M; Tzvetkov, Mladen V et al. (2014) PharmGKB summary: tramadol pathway. Pharmacogenet Genomics 24:374-80|
|Barbarino, Julia M; Kroetz, Deanna L; Altman, Russ B et al. (2014) PharmGKB summary: abacavir pathway. Pharmacogenet Genomics 24:276-82|
Showing the most recent 10 out of 69 publications